| Literature DB >> 24651734 |
S M Gephart1, A R Spitzer2, J A Effken1, E Dodd2, M Halpern3, J M McGrath4.
Abstract
OBJECTIVE: Better measures are needed to identify infants at risk for developing necrotizing enterocolitis (NEC) and facilitate communication about risk across transitions. Although NEC is multi-factorial, quantification of composite risk for NEC in an individual infant is not clearly defined. The objective of this study was to describe the derivation, validation and calibration testing of a novel clinical NEC risk index, GutCheck(NEC). Individual risk factors were weighted to assess composite odds of developing NEC. GutCheck(NEC) is designed to improve communication about NEC risk and coordination of care among clinicians across an infant's clinical course. STUDYEntities:
Mesh:
Year: 2014 PMID: 24651734 PMCID: PMC4420242 DOI: 10.1038/jp.2014.37
Source DB: PubMed Journal: J Perinatol ISSN: 0743-8346 Impact factor: 2.521
Univariate Analysis of Risk Factors
| Risk Item | β | Std. | t | sig |
|---|---|---|---|---|
| Gestational age (weeks) | 0.01 | 0 | 2.52 | 0.012 |
| Birth weight (grams) | 0 | 0 | −9.36 | <.0001 |
| Outborn | 0.01 | 0 | 4.02 | <.0001 |
| Male | 0.01 | 0 | 2.9 | 0.004 |
| Antenatal Steroids | 0 | 0 | −1.07 | 0.286 |
| African-American | 0.01 | 0 | 2.89 | 0.004 |
| Hispanic | 0.01 | 0 | 2.07 | 0.039 |
| 5 minute Apgar < 7 | −0.01 | 0 | −2.2 | 0.028 |
| 10 minute Apgar < 7 | −0.01 | 0.01 | −1.91 | 0.056 |
| Temperature < 36 degrees at one hour of age | −0.02 | 0 | −5.64 | <.0001 |
| High frequency ventilation on day of life 7 | −0.02 | 0 | −6.41 | <.0001 |
| Indomethacin | −0.01 | 0 | −3.85 | <.0001 |
| Indomethacin and dexamethasone | −0.02 | 0.01 | −3.8 | <.0001 |
| Dopamine, dobutamine or milrinone | 0.05 | 0 | 10.73 | <.0001 |
| Hypotension | 0.01 | 0 | 1.41 | 0.157 |
| Metabolic acidosis | 0.02 | 0 | 6.15 | <.0001 |
| Probiotics given (formulation not specified) | 0.04 | 0.01 | 3.21 | 0.001 |
| Early sepsis | −0.02 | 0.01 | −2 | 0.045 |
| Late sepsis | 0.03 | 0 | 5.69 | <.0001 |
| Received H2 blocker | 0.07 | 0.01 | 8.28 | <.0001 |
| Patent Ductus Arteriosus, any treatment | 0.01 | 0 | 3.35 | 0.001 |
| Packed Red Blood Cell (PRBC) transfusion | 0.04 | 0 | 14.07 | <.0001 |
| 2 or more positive cultures (blood, urine, other) | 0.02 | 0.01 | 3.75 | <.0001 |
| Human milk at day of life 7 and 14 | 0.02 | 0.01 | 3.4 | 0.001 |
| Human milk at day of life 7,14 and discharge | 0 | 0.01 | −0.6 | 0.546 |
| Human milk at day of life 7 | 0 | 0 | −0.82 | 0.411 |
| Human milk at day of life 14 | 0 | 0 | −0.13 | 0.899 |
| NICU volume | 0 | 0 | 2.12 | 0.034 |
| Unit NEC rate | 0.03 | 0 | 18.75 | <.0001 |
t depicts difference between NEC and no-NEC infants in the derivation set (n=35 013)
Logistic Model with Weighted Risk Items
| Risk Item | β | GutCheckNEC | Sig. | Odds | 95% CI | |
|---|---|---|---|---|---|---|
| Human Milk at both day 7 and day 14 of | −0.34 | −3 | < 0.001 | 0.71 | 0.62 | 0.82 |
| Late Sepsis | 0.40 | 4 | < 0.001 | 1.49 | 1.30 | 1.72 |
| Packed Red Blood Cell Transfusion | 0.81 | 8 | < 0.001 | 2.26 | 2.02 | 2.52 |
| NICU NEC rate (< 2%) | 0 | < 0.001 | ||||
| NICU NEC rate (2-4.99%) | 0.94 | 9 | < 0.001 | 2.56 | 1.62 | 4.03 |
| NICU NEC rate (5-7.99%) | 1.61 | 16 | < 0.001 | 5.00 | 3.19 | 7.84 |
| NICU NEC rate (8-11.99%) | 1.87 | 19 | < 0.001 | 6.49 | 4.12 | 10.22 |
| NICU NEC rate (>12%) | 2.29 | 23 | < 0.001 | 9.84 | 6.13 | 15.79 |
| Gestational Age ≥ 32 weeks | 0 | < 0.001 | ||||
| Gestational Age 28-32 weeks | 0.78 | 8 | < 0.001 | 2.17 | 1.68 | 2.82 |
| Gestational Age < 28 weeks | 0.87 | 9 | < 0.001 | 2.37 | 1.78 | 3.16 |
| Black Race | 0.20 | 2 | < 0.001 | 1.22 | 1.09 | 1.35 |
| Hispanic | 0.17 | 2 | 0.007 | 1.18 | 1.05 | 1.34 |
| Probiotics | −0.54 | −5 | 0.005 | 0.58 | 0.40 | 0.85 |
| Outborn | 0.27 | 3 | < 0.001 | 1.31 | 1.17 | 1.46 |
| Metabolic Acidosis | 0.29 | 3 | < 0.001 | 1.33 | 1.18 | 1.50 |
| Dopamine, Dobutamine or Milrinone | 0.41 | 4 | < 0.001 | 1.51 | 1.36 | 1.69 |
| Two or more positive blood or urine | 0.16 | 2 | 0.038 | 1.18 | 1.01 | 1.37 |
Figure 1a. Discrimination of GutCheckNEC for medical NEC in the case-control validation set
b. Discrimination of GutCheckNEC for surgical NEC in the case-control validation set
c. Discrimination of GutCheckNEC for NEC leading to death in the validation set
Discrimination of GutCheckNEC
| AUC | Sensitivity | Specificity | AUC | Sensitivity | Specificity | |
|---|---|---|---|---|---|---|
| NEC Subset | Validation Set | Calibration Set Specificity | ||||
| All NEC | 0.67 (0.61-0.73) | 0.65 | 0.60 | 0.76 (0.75-0.78) | 0.62 | 0.76 |
| NEC-Medical | 0.57 (0.50-0.64) | 0.55 | 0.53 | 0.72 (0.70-0.74) | 0.54 | 0.75 |
| NEC-Surgical | 0.73 (0.66-0.80) | 0.80 | 0.57 | 0.84 (0.82-0.84) | 0.79 | 0.75 |
| NEC leading to death | 0.65 (0.55-0.76) | 0.72 | 0.54 | 0.83 (0.81-0.85) | 0.75 | 0.74 |
Data are presented as Areas Under the Curve with 95% Confidence Interval
Sensitivity is presented at a cut point score > 32
Specificity is presented at a cut point score > 32
Figure 3GutCheckNEC Risk Index